Patient-reported outcomes (PROs) capture symptoms, functioning, quality of life, treatment burden and priorities directly from patients. Their integration into Molecular Tumor Board (MTB)-guided care remains limited and particularly challenging, as recommendations often involve off-label therapies, sparse evidence and...
L. Gräßel, S. Yacob, C. Strantz et al.· npj Precision Oncology· 0 citations
Immune checkpoint inhibitors (ICIs) and BRAF/MEK kinase inhibitors have substantially improved survival in advanced melanoma; however, therapeutic resistance and severe toxicities underscore the ongoing need for alternative strategies. Here, we evaluate the clinical utility of multi-omic profiling, biomarker-stratified...
T. Lowinus, V. Schipperges, P. Metzger et al.· npj Precision Oncology· 0 citations
Improved survival in multiple myeloma (MM) patients after high-dose chemotherapy, autologous hematopoietic cell transplantation (auto-HCT), and novel agents has led to an increasing incidence of therapy-related hematological malignancies (t-HM), although optimal management remains unclear, particularly the role of allo...
M. Maulhardt, A. Angleitner, J. Büntzel et al.· Frontiers in Oncology· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.